Advances in the development of drug-coated balloon

Join Florim Cuculi and Rony Mathew at this EuroPCR 2025 roundtable to assess the evolution of drug-coated balloons (DCBs) and their role in daily practice.

DCBs offer a compelling alternative to stent implantation in selected cases. However, they are not interchangeable—each is built using different drugs, carriers, and technologies, meaning there is no class effect.

The Protégé balloon exemplifies how design can make a difference. Its flexibility and protected drug coating allow for smooth navigation through complex anatomies and accurate drug delivery into the lesion, even in challenging settings such as calcified circumflex arteries.

Which lesions benefit most from a DCB strategy? Are current data sufficient to support broader use? What kind of evidence is emerging in de novo lesions?

This discussion offers practical insights into current decision-making and what lies ahead in the DCB space.

Watch the full roundtable for key insights on drug-coated balloon use and future directions.

This interview was filmed at EuroPCR 2025: see more videos here.